NCT07100054View on ClinicalTrials.gov

Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
CDK4/6 InhibitorBreast CancerCYP3A4 Protein, HumanDrug InteractionPharmacogenetic Testing
Interventions
GENETIC

Whole gene sequencing

Whole gene sequencing of CYP3A4 and PXR

OTHER

Drug-drug interaction analysis

Evaluating potential drug interactions with CYP3A4 inhibitors and inducers

OTHER

Biomarker analysis

Determination of circulating CYP3A4 mRNA, and 4b-hydroxycholesterol

Trial Locations (1)

Unknown

London Health Sciences Centre Research Institute, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT07100054 - Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors | Biotech Hunter | Biotech Hunter